Impact Report Web Header 2024

Forschung

As a leader in advancing the science of FTD, AFTD works with a diverse, global community to further biomarker discovery and development of the first approved therapies, and to empower people impacted to engage in research.

Roundtable_IR24
Representatives from 16 international companies actively pursuing FTD drug development joined AFTD staff to plan the 2023 FTD Research Roundtable meeting.

The inaugural FTD-Forschungsrundtisch, held in September 2023, welcomed more than 100 participants from biopharma, academia, government agencies, advocacy organizations, and genetic families to identify barriers and common challenges in FTD-focused drug development and propose best practices for designing clinical trials.

In collaboration with the FTD Disorders Registry, AFTD presented three Perspektiven in der FTD-Forschung Webinare, addressing topics such as legal considerations and protections regarding genetic counseling and predictive testing; clinical trials focused on CBS and PSP, two FTD disorders; and interventions being developed for genetic forms of the disease.

IR 2024 - Webinars

In early 2024, the FTD Disorders Registry launched an upgraded platform to improve user experience, data collection and management, and accessibility for a global community of researchers. Registry staff shared information on how to participate in research at AFTD’s 2024 Education Conference.

Klicken hier to learn more about the FTD Disorders Registry.

Registry Staff at AEC - IR2024
John_Replogle - square headshot

“Awards like the Holloway Postdoctoral Fellowship make a significant impact in our ability to drive research in the direction we want to go – it’s made a big difference to my work studying TMEM106B.”

John Replogle, PhD, a Postdoctoral Fellow at the National Institutes of Health, who is studying the protein’s impact on neuronal health and its role in neurodegeneration

Holloway Family Fund

IR2024 - Holloway 2023
Das 2023 Holloway Summit featured discussions on overcoming shared challenges in biomarker discovery.
Kristin H. and Board @ Holloway Summit - IR24
AFTD Board members at the 2023 Holloway Summit (L to R): Kristin Schneeman, Gail Andersen, Kristin Holloway, Board Chair Kimberly Pang Torres

Established in 2021 by AFTD Board member Kristin Holloway and the Holloway family in honor of Kristin’s husband, Lee, the Holloway Family Fund expanded our Postdoctoral Fellowship program and created the Holloway Summit, an annual meeting designed to convene global leaders in FTD-focused research to propose solutions for therapeutic development.

Awards and Grants

In fiscal year 2024, we awarded $1.57 million in new research grants supporting nine studies, including:

McEachin - Square

Zachary McEachin, PhD | Emory School of Medicine
2024 Pathways for Hope Pilot Grant

Bunnik - Square

Eline Bunnik, PhD | Erasmus Medical Center
2024 Well-Being in FTD Pilot Grant

popli-tanav

Tanav Popli, MD | Universität von Michigan
Ausbildungsstipendium für klinische Forschung in FTD

To learn more about other AFTD-funded projects, visit theaftd.org/for-researchers/grants-funded